Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience with Potential for Improved Efficacy?

Evidence-Based GI: An ACG Publication and Podcast - A podcast by American College of Gastroenterology - Wednesdays

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Elie S. Al Kazzi, MD, MPH discuss “Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY),” Gastroenterology. 2024;167:919–933.